skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: As a new member of 5i Research, I first want to thank you for the service you provide. Fantastic.

I am reviewing the Canadian portion of my RRSP, sector by sector. I have a balanced approach and 15+ years ahead of me before transferring to a RRIF.

I find myself a bit underweight and concentrated in Healthcare, owing only NHW.UN (4% of Canadian portfolio). I was thinking of switching half into CSH.UN for diversification within the Real Estate/Healthcare space, then add a 3% position in GUD for more growth. What are your thoughts?

Note: The US portion of my RRSP, which is half the size of my Canadian portfolio, is invested in Mutual funds with Healthcare/Big Pharma representing about 16% of my US holdings. So my strategy would bring Healthcare to 10% overall in my RRSP.

Thx.
Read Answer Asked by Christian on August 25, 2017
Q: On Nov 26, 2016 I asked if CRH has risen too quickly and was likely to decline materially. You mentioned the fundamentals were strong and it was not like other prominent TSX collapses of recent years.

Now that the stock has collapsed rather predictably I ask why do you still think share price momentum is a good thing to chase.
Read Answer Asked by Chris on August 25, 2017
Q: Hello 5i,
If I am looking at starting a position in SIS when it starts showing positive "price momentum", what are the 3 -5 primary factors that you consider to determine "price momentum" and also could you please quantify the parameters that you prefer (for example, if one of your factors is RSI, do you favour 14 or another value)?
Read Answer Asked by Richard on August 25, 2017
Q: Hi Team,
Following a question about Canadian and US health care sector opportunities, I am trying compare and contrast IBB (iShares Nasdaq Biotechnology ETF) with XBI (SPDR S&P Biotech ETF). I realize the former focuses on large companies and has more concentrated positions in top holdings while the latter focuses on small companies with a more even distribution of holdings. What are your thoughts about a risk/return trade off between the two ETFs and what timeframe would you be considering to hold either one for an investment thesis to pan out? If you had to pick one, which would it be and why?
Many thanks, Michael
Read Answer Asked by Michael on August 18, 2017
Q: For those deeply under water on CRH, still in the stock and looking for positives:

1) Look at the Cash Flow Statement (not the Income Statement):
- This business makes real cash... CF-Operation is $9.75M
- Deducting 'non-controlling interest of $2.2 still leaves $7.5M
- CF Financing noisy due to retirement of high interest Crown and replacing by Scotia 3.5% loan - but there is cash generated for acquisition, debt replayment, etc.


2) Mawer Management is not selling... they are buying (as of end July)!
- Guy wondered about Mawer on July 16. I also track them as they are the best Management firm. Like everyone, they will have their share of losers and this may be one (they are sure deep under water) - so no guarantee but they are buying, not selling:
- Q2 data from Morningstar, they bought 924K shares and owned 6.43%
- How about July when the CMS reimbursement rate occurred? They bought +24% more (they manage the 'BMO enterprise' fund)
- How about after Q2? That we don't know yet...


3) One Director bought shares (independent Director, not Management)
- Per canadianinsider, Tood Patrick bought 50,000 shares on Aug 9/10
- Still would like to see the CEO or other Management buy but this is a first sign.
Read Answer Asked by Jennifer on August 17, 2017
Q: Hi there, just looking for further clarification on PLI, have you assessed the risks in Prometic not receiving approval for the Plasminogen BLA from the FDA? Could it be possible that PLI raised further funds very quickly, at a substantial discount, at $1.70, trading well over $2 at that time, suspecting they will not be approved?
"The Corporation is responding diligently to all FDA requests in relation to the BLA review. The Corporation will provide further updates on the expected timeline of regulatory approval as soon as available"
Could it be possible that PLI is suspecting the FDA is looking for further clinical data for approval, which could take an additional 12 to 18 months for final approval? Have you assessed these types of risks in your modelling for the Growth Portfolio holding? Where do you see the stock price trading at, if the above scenario does occur?
Hope I am wrong above!
Thanks!
Read Answer Asked by Hussein on August 17, 2017
Q: While I don't own GUD yet, I keep seeing it reviewed positively and therefore read the FP article you linked:
- "Laurentian Bank Securities analyst sees revenue rising to $6.9 million this year and $52.3 million in 2018 as more drugs work their way through approvals..."

Do you agree with the assessment of projected 2018 revenues of 52.3 million?
If so, what would the implied price of GUD be the end of 2018 based on revenues of 52.3 million?

Read Answer Asked by Curtis on August 17, 2017
Q: I was watching "This Old House" on PBS last night. They featured a Savaria lift which they installed for a wheel chair bound person. The elevator appeared well designed, simple to construct and worked well. Thought you might be interested.

By the way, unlike Dave, I have made a pile of money by following 5i Research recommendations. I note PBH hit a new high yesterday. (My main contribution to stock management is my ability to procrastinate instead of panic selling!)

Jim
Read Answer Asked by James on August 17, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!